Folfiri-Aflibercept vs. Folfiri-Bevacizumab as Second Line Treatment of RAS Mutated Metastatic Colorectal Cancer in Real Practice

Background: There are no clinical studies comparing the efficacy of bevacizumab vs.aflibercept in association with folfiri in RAS mutated (RAS-M) metastatic colorectal cancer patients (mCRC) pretreated with folfox and bevacizumab. Patients and Methods: Consecutive RAS-M unresectable mCRC patients pr...

詳細記述

保存先:
書誌詳細
出版年:Front Oncol
主要な著者: Ottaiano, Alessandro, Capozzi, Monica, Tafuto, Salvatore, De Stefano, Alfonso, De Divitiis, Chiara, Romano, Carmela, Avallone, Antonio, Nasti, Guglielmo
フォーマット: Artigo
言語:Inglês
出版事項: Frontiers Media S.A. 2019
主題:
Oncology
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6700318/
https://ncbi.nlm.nih.gov/pubmed/31456948
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2019.00766
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料